Search results
Showing 121 to 135 of 208 results for lymphoma
Awaiting development Reference number: GID-TA11811 Expected publication date: TBC
Lymphoma (diffuse large B-cell, untreated) – liposomal vincristine [ID1123]
Discontinued Reference number: GID-TA11208
Discontinued Reference number: GID-TA10185
Awaiting development Reference number: GID-TA11050 Expected publication date: TBC
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
Discontinued Reference number: GID-TA10140
Evidence-based recommendations on hand transplant surgery (allotransplantation). This involves transplanting a hand from a recently deceased donor onto the amputated stump.
View recommendations for HTG254Show all sections
Sections for HTG254
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
Discontinued Reference number: GID-TA10480
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]
Discontinued Reference number: GID-TA11173
Awaiting development Reference number: GID-TA11849 Expected publication date: TBC
Discontinued Reference number: GID-TA10437
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]
Discontinued Reference number: GID-TA10750
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.